Coverage
-
December 03, 2015
AstraZeneca AB blasted Mylan Laboratories Ltd.'s contention that New Jersey is the wrong venue for a patent infringement lawsuit over AstraZeneca's breast cancer drug, arguing Wednesday that it was the generic-drug maker's Garden State subsidiary that filed the application to market its version of the drug.
2 other articles on this case.
View all »